A differentiated thyroid carcinoma-specific graded prognostic assessment for brain metastases: derivation in a 10,306-patient cohort and external validation - Scorecard - MDSpire

A differentiated thyroid carcinoma-specific graded prognostic assessment for brain metastases: derivation in a 10,306-patient cohort and external validation

  • By

  • Hamza A. Salim

  • Sarimar Agosto

  • Heba Al Qudah

  • Kim Learned

  • Mark Zafereo

  • Jennifer Wang

  • Mimi I. Hu

  • Ahmed Msherghi

  • Naifa Busaidy

  • F. Eymen Ucisik

  • Sarah Hamidi

  • Hussein Tawbi

  • Rami W. Eldaya

  • Jing Li

  • Max Wintermark

  • Maria E. Cabanillas

  • April 14, 2026

  • 0 min

Share

Clinical Scorecard: A Prognostic Grading System for Brain Metastases in Differentiated Thyroid Carcinoma: Development and Validation in a Cohort of 10,306 Patients

At a Glance

CategoryDetail
Condition
Key MechanismsIndolent malignancy with potential for advanced disease and distant metastases, including rare brain metastases, which significantly worsen prognosis.
Target Population
Care Setting

Key Highlights

  • Brain metastases in DTC occur in 0.1–1.3% of patients, with survival influenced by various factors.
  • Median overall survival after diagnosis of brain metastases ranges from 3 to 60 months, depending on patient and disease characteristics.

Guideline-Based Recommendations

Diagnosis

    Management

    • Utilize the DTC-GPA for clinical decision-making and treatment planning, considering specific treatment modalities.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Patients with differentiated thyroid carcinoma and confirmed brain metastases.

        Management strategies should be individualized based on prognostic factors.

        Clinical Best Practices

        • Incorporate performance status and extracranial disease burden in treatment planning, and emphasize the importance of molecular profiling for targeted therapy options.

        References

        Original Source(s)

        A differentiated thyroid carcinoma-specific graded prognostic assessment for brain metastases: derivation in a 10,306-patient cohort and external validation

        • by Hamza A. Salim, Sarimar Agosto, Heba Al Qudah, Kim Learned, Mark Zafereo, Jennifer Wang, Mimi I. Hu, Ahmed Msherghi, Naifa Busaidy, F. Eymen Ucisik, Sarah Hamidi, Hussein Tawbi, Rami W. Eldaya, Jing Li, Max Wintermark, Maria E. Cabanillas

        • April 14, 2026

        Related Content

        Temporal Changes in Brain Metastasis Resection Sites Following Adjuvant Gamma Knife Radiosurgery

        A pharmacodynamic study of rapid lactate metabolic modulation by intravenous L-arginine in brain metastases

        Neurobehavioral outcomes and associated risk factors in pediatric brain tumor survivors